In the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to maximise benefits of already approved drugs, as well as developing new ones. Johnson & Johnson’s Janssen unit is taking this approach with…
J&J strengthens R&D into COVID-19 vaccine with US government
Johnson & Johnson has announced it has expanded a collaboration with a US government agency to hasten development of its coronavirus vaccine, as fears mount about the scale of the outbreak that is now called COVID-19. As previously reported by…
FDA Slaps Clinical Hold on LogicBio’s Gene Therapy Treatment
Shares of LogicBio have plunged more than 25% in premarket trading after the company disclosed late Monday that the U.S. Food and Drug Administration (FDA) placed a clinical holdon its proposed gene therapy treatment for methylmalonic academia (MMA). In January,…
Genentech, Lilly Fail to Meet Primary Endpoint in Alzheimer’s Trial
Alzheimer’s disease continues to be a tough nut to crack. A specially designed clinical trial that was the first disease prevention trial to study Alzheimer’s disease drugs with different mechanisms of action from two different pharmaceutical companies failed to hit…
Eylea Reduces Chance of Vision-Threatening Events by 75% in NDPR Patients, Study Shows
Late-stage data released from Regeneron highlights the importance of proactively providing Eylea to patients who have been diagnosed with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) in order to prevent issues that could lead to the loss of vision.…
Myovant to Seek Regulatory Approval of Uterine Fibroid Treatment Following Positive Late-Stage Trial
More than five million women suffer from symptoms of uterine fibroids, with more than half of them estimated to have received inadequate treatment. However, new data released by Myovant shows that concerns of inadequate treatment could soon change. This morning,…
Gilead closes in on second CAR-T approval in US
The FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Gilead’s Kite unit intended to treat mantle cell lymphoma (MCL). The US regulator has just started a six-month priority review of KTE-X19…
FDA to quickly review Novartis’ capmatinib in rare lung cancer
The FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung cancer. Novartis said it has applied for capmatinib, developed in partnership with Incyte, to be marketed as a MET inhibitor for…
Life Sciences Skills Strategy suggests need for 133,000 extra jobs by 2030
The Life Sciences sector is expected to demand an extra 133,000 skilled scientific jobs through to 2030 – according to the Life Sciences 2030 Skills Strategy. The report, published by Science Industry Partnership (SIP) in collaboration with the Association of the…
Abbott wins breakthrough tag for fully implantable LVAD system, following Medtronic
Dive Brief: Abbott said Tuesday it won a breakthrough device designation for a fully implantable left ventricular assist device (LVAD), which could help speed the experimental technology through FDA review. The devices are intended for use in people with advanced…
